FORA Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

FORA Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,143	Closed	-$16K	–	780
2020 Q4	$16K	Buy	+2,143	New	+$11K	﹤0.01%	887

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

FORA Capital's BCRX Position: Q1 2021 in Review

FORA Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2021, closing a stake of 2,143 shares — an estimated $16K sold.

FORA Capital first reported a position in BCRX in Q4 2020 and held it in 1 quarter. The position peaked at $16K in Q4 2020. 191 funds tracked by Wall St. Rank hold BCRX as of Q1 2021.

FORA Capital reported no remaining BioCryst Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
FORA Capital sold 2,143 BioCryst Pharmaceuticals shares in Q1 2021, an estimated $16K.
FORA Capital first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 1 quarter.
FORA Capital's BioCryst Pharmaceuticals position peaked at $16K in Q4 2020.
191 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2021.

Based on FORA Capital's 13F filing for Q1 2021, filed 17 May 2021.